相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future
Hitomi Yamashita et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment
A. Pawlowska et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2019)
Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy
Liisa Chang et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand-1 (PD-L1) in ovarian cancer
Maureen L. Drakes et al.
JOURNAL OF OVARIAN RESEARCH (2018)
Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
Klaus Pietzner et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Advances in ovarian cancer therapy
Alexander J. Cortez et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
Xinxin Zhu et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2017)
Identification of essential genes for cancer immunotherapy
Shashank J. Patel et al.
NATURE (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw et al.
CANCER DISCOVERY (2017)
Immunotherapy and patients treated for cancer with microsatellite instability
Raphael Colle et al.
BULLETIN DU CANCER (2017)
High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine
Zoran Gatalica et al.
FAMILIAL CANCER (2016)
Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas
Peter F. Rambau et al.
HISTOPATHOLOGY (2016)
Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application
Masaki Mandai et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Deficient mismatch repair: Read all about it
Susan Richman
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Ovarian Endometrioid Adenocarcinoma: Incidence and Clinical Significance of the Morphologic and Immunohistochemical Markers of Mismatch Repair Protein Defects and Tumor Microsatellite Instability
Anil Aysal et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Wei-Ting Hwang et al.
GYNECOLOGIC ONCOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ashour Ahmed Ahmed et al.
JOURNAL OF PATHOLOGY (2010)
Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger
Kristin C. Jensen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma
Andres G. Chiesa-Vottero et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2007)
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion
Christian Blank et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Systematic review of microsatellite instability and colorectal cancer prognosis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
